STOCK TITAN

Alpha Cognition appoints Caren Deardorf as director

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Alpha Cognition Inc. (ACOG) appointed Caren Deardorf as a director, effective November 11, 2026. Deardorf is a biotechnology executive and public company director with more than 30 years of experience in commercialization, corporate strategy, portfolio prioritization, business development and company building. She has been Chief Business and Strategy Officer at Neutrolis Inc. since August 2025.

Under ACOG’s non-employee director annual equity grant, Deardorf received 755 restricted stock units and 1,020 stock options. The options have an exercise price of $8.62 per share, and both awards vest one year after the date of grant.

Filing Explained

The board reconstituted its committees after Deardorf’s appointment, placing her on both the Audit Committee and the Governance and Nomination Committee.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Restricted stock units 755 restricted stock units Initial grant in connection with Deardorf’s director appointment
Stock options 1,020 stock options Initial grant in connection with Deardorf’s director appointment
Exercise price $8.62 per share Exercise price of the stock options
Vesting One year after the date of grant Applies to both the restricted stock units and stock options
restricted stock units financial
"received an initial grant of 755 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price financial
"The stock options have an exercise price of $8.62 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"Both the restricted stock units and the stock options vest one year after the date of grant"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did ACOG grant Caren Deardorf?

ACOG granted Deardorf 755 restricted stock units and 1,020 stock options. The options have an exercise price of $8.62 per share, and both awards vest one year after the date of grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001655923 A1 00-0000000 0001655923 2026-11-05 2026-11-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 5, 2026

 

Alpha Cognition Inc.

(Exact name of registrant as specified in its charter)

 

British Columbia   001-42403   N/A
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification Number)

 

1452 Hughes Rd., Ste 200
Grapevine, Texas
  76051
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 858-344-4375

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol   Name of each exchange on which
registered:
Common Shares, no par value   ACOG   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 5, 2026, the board of directors (the “Board”) of Alpha Cognition Inc. (the “Company”) appointed Caren Deardorf as a director of the Company effective November 11, 2026.

 

Ms. Deardorf is a biotechnology executive and public company director with more than 30 years of experience spanning commercialization, corporate strategy, portfolio prioritization, business development, and company building. She has helped organizations create and preserve value through category & brand leadership, development-to commercial transitions, portfolio decisions, out-licensing, and M&A pathways. Ms. Deardorf is currently Chief Business and Strategy Officer at Neutrolis Inc., since August of 2025, where she is responsible for leading business development, clinical program strategy, and commercial/operational build for a private autoimmune company in transition to clinical stage. Prior to that, she served as Chief Commercial and Strategy Officer at Editas Medicine (2023-2025), Chief Commercial and Strategy Officer at Magenta Therapeutics (2021-2023) and Chief Commercial Officer at Ohana Biosciences (2019-2021). Ms. Deardorf also recently served on the board of directors of Crinetics Pharmaceuticals (2022-2026) and NeuroSense Therapeutics (2021-2024). Ms. Deardorf received an M.B.A. from Babson College- Olin Graduate School of Business and a B.S., Biology (Premed) with French concentration from Tufts University.

 

Ms. Deardorf will receive compensation in accordance with the Company’s previously disclosed non-employee director compensation policy.

 

In accordance with the Company’s non-employee director annual equity grant, in connection with her appointment, Ms. Deardorf received an initial grant of 755 restricted stock units and 1,020 stock options. The stock options have an exercise price of $8.62 per share. Both the restricted stock units and the stock options vest one year after the date of grant.

 

There is no arrangement or understanding between Ms. Deardorf and any other persons pursuant to which Ms. Deardorf was appointed as a director. There is no family relationship between Ms. Deardorf and any director or executive officer of the Company, and except as stated herein, Ms. Deardorf does not have any direct or indirect material interest in any transaction with the Company or its subsidiaries of the type required to be disclosed pursuant to Item 404(a) of Regulation S-K, and no such transaction is currently contemplated.

 

Following the appointment of Ms. Deardorf to the Board, the Board, upon recommendation of its Governance and Nomination Committee, re-constituted its committees as follows:

 

Compensation Committee

Phillip Mertz (Chair)

Dr. Robert Wills

Kenneth Cawkell

 

Audit Committee

Bethany Sensenig (Chair)

Dr. Robert Wills

Caren Deardorf

 

Governance and Nomination Committee

Rajeev “Rob” Bakshi (Chair)

Bethany Sensenig

Caren Deardorf

 

1

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ALPHA COGNITION INC.
   
  By: /s/ Michael McFadden
    Michael McFadden
    Chief Executive Officer
     
Dated: November 12, 2026  

 

3

 

Filing Exhibits & Attachments

3 documents

Keep reading